T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant
NCT ID: NCT00048464
Last Updated: 2006-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
35 participants
INTERVENTIONAL
2002-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will undergo a steady state leukapheresis (Xcellerate Leukapheresis) to obtain peripheral blood mononuclear cells that will be used to produce Xcellerated T Cells. During the Xcellerate Process, T cells will be activated and expanded ex vivo by co-stimulation with anti-CD3 and anti-CD28 monoclonal antibodies covalently attached to super-paramagnetic microbeads. While the Xcellerated T Cells are being produced at Xcyte Therapies, patients will be treated with a standard mobilization regimen consisting of cyclophosphamide and filgrastim (Neupogen; G-CSF), followed by a second leukapheresis for collection of peripheral blood stem cells. Patients will be treated with a standard high-dose chemotherapy regimen for multiple myeloma consisting of single agent melphalan (200mg/m2). Patients will then receive their peripheral blood stem cells followed by post-transplant filgrastim for neutrophil recovery. Three days (Day 3) following stem cell infusion, patients will receive a single dose Xcellerated T Cells.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Infusion of Activated & Expanded Autologous T Cells
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Durie-Salmon Stage II or III disease at any time since diagnosis
Exclusion Criteria
* Lymphocyte subsets by flow cytometry demonstrating CD3+ \>= 10% of the peripheral white blood cell count, and CD4+/CD8+ \>= 0.30. Test must be obtained following completion of induction therapy.
* Meets all institutional criteria for and has institutional approval to undergo autologous peripheral blood stem cell transplantation
* Age \>= 18 years old and \<=70 years old
* ECOG performance status of 0 or 1
* Life expectancy \> 6 months
* Females of child-bearing potential must have a negative serum bHCG test and be willing to use effective contraception (i.e. a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, or condom with spermicide, or abstinence) up to Day 180.
* Negative test results for current/active infection with HIV-1, HIV-2, hepatitis B, and hepatitis C within 60 days of registration.(Antibody, antigen and nucleic acid tests acceptable, depending on institutional standards.)
* Corrected serum calcium \< 11 mg/dL, and no evidence of symptomatic hypercalcemia. (Corrected serum calcium is calculated by adding 0.8 mg/dL to the measured serum calcium for every 1 g/dL that the serum albumin falls below 4.0 g/dL.)
* Serum total bilirubin and SGPT (ALT) \< 2.0 times the upper limit of normal
* Serum creatinine \< 2.0 mg/dL
* No detectable human anti-mouse antibody (HAMA) titer, and no history of allergies to mice or murine (mouse) proteins
* The patient must be able to comprehend and have signed the informed consent
* Diagnosis of any of the following cancers:
* POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein \[M-protein\] and skin changes)
* Non-secretory myeloma
* Plasma cell leukemia
* Diagnosis of amyloidosis
* Progression or relapse presently or in the past, during or following therapy for multiple myeloma
* Previous hematopoietic stem cell transplantation
* Use of corticosteroids (glucocorticoids) within 21 days of registration
* Infection requiring treatment with antibiotics, antifungal, or antiviral agents within seven days of registration
* Participation in any clinical trial, within four weeks prior to registration on this trial, which involved an investigational drug or device
* History of malignancy other than multiple myeloma within five years of registration, except adequately treated basal or squamous cell skin cancer. Any other exceptions must be discussed with Xcyte Therapies' Medical Monitor prior to registration.
* History of an autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosis) requiring systemic treatment. Hypothyroidism without evidence of Grave's Disease or Hashimoto's thyroiditis is permitted.
* Evidence of spinal cord compression
* Major organ system dysfunction including (but not limited to): New York Heart Association Class III or IV, pulmonary disease requiring the use of inhaled steroids or bronchodilators, renal, hepatic, gastrointestinal, neurologic, or psychiatric dysfunction which would impair patient's ability to participate in the trial
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xcyte Therapies
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cedars Sinai Medical Center
Los Angeles, California, United States
University of California, San Diego
San Diego, California, United States
University of California, San Francisco
San Francisco, California, United States
Johns Hopkins Medical Institute
Baltimore, Maryland, United States
Washington University
St Louis, Missouri, United States
Hackensack University
Hackensack, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Levine BL, Bernstein WB, Aronson NE, Schlienger K, Cotte J, Perfetto S, Humphries MJ, Ratto-Kim S, Birx DL, Steffens C, Landay A, Carroll RG, June CH. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med. 2002 Jan;8(1):47-53. doi: 10.1038/nm0102-47.
Thomas AK, June CH. The promise of T-lymphocyte immunotherapy for the treatment of malignant disease. Cancer J. 2001 Nov-Dec;7 Suppl 2:S67-75.
June CH. Can't get any help? New approaches for adoptive immunotherapy of cancer. J Immunother. 2001 Sep-Oct;24(5):389-91. No abstract available.
Frohlich, M., Grosmaire, L., Xu, J., Rasmussen, A., Roehrs, H., Lindgren, R., Ferrand, C., Tiberghien, P., Leis, J., and Bonyhadi, ML: Xcellerate: a novel autologous T cell immunotherapeutic approach for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). The IX International Workshop on CLL.2002.
Li Q, Yu B, Grover AC, Zeng X, Chang AE. Therapeutic effects of tumor reactive CD4+ cells generated from tumor-primed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies. J Immunother. 2002 Jul-Aug;25(4):304-13. doi: 10.1097/00002371-200207000-00002.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XT003
Identifier Type: -
Identifier Source: org_study_id